JPWO2019165116A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019165116A5 JPWO2019165116A5 JP2020544661A JP2020544661A JPWO2019165116A5 JP WO2019165116 A5 JPWO2019165116 A5 JP WO2019165116A5 JP 2020544661 A JP2020544661 A JP 2020544661A JP 2020544661 A JP2020544661 A JP 2020544661A JP WO2019165116 A5 JPWO2019165116 A5 JP WO2019165116A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cancer
- host cell
- signaling domain
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 77
- 102000037240 fusion proteins Human genes 0.000 claims description 77
- 210000004027 cells Anatomy 0.000 claims description 58
- 230000011664 signaling Effects 0.000 claims description 36
- 101700033362 CD28 Proteins 0.000 claims description 35
- 102100019461 CD28 Human genes 0.000 claims description 35
- 229920000023 polynucleotide Polymers 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007172 antigens Proteins 0.000 claims description 20
- 102000038129 antigens Human genes 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 17
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- -1 CARD1 Proteins 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 125000001235 proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 13
- 102100007290 CD274 Human genes 0.000 claims description 10
- 101710012053 CD274 Proteins 0.000 claims description 10
- 101700054183 CTLA4 Proteins 0.000 claims description 10
- 102100005310 CTLA4 Human genes 0.000 claims description 10
- 102100007289 PDCD1LG2 Human genes 0.000 claims description 10
- 101710011976 PDCD1LG2 Proteins 0.000 claims description 10
- 102100008790 TNFRSF14 Human genes 0.000 claims description 10
- 101710040448 TNFRSF4 Proteins 0.000 claims description 10
- 102100013135 TNFRSF4 Human genes 0.000 claims description 10
- 101710040535 TNFRSF9 Proteins 0.000 claims description 9
- 102100009537 TNFRSF9 Human genes 0.000 claims description 9
- 230000003834 intracellular Effects 0.000 claims description 9
- 108060004270 LAG3 Proteins 0.000 claims description 8
- 102100017213 LAG3 Human genes 0.000 claims description 8
- 102100017643 SLAMF1 Human genes 0.000 claims description 8
- 101710038603 TNFRSF18 Proteins 0.000 claims description 8
- 102100003096 TNFRSF18 Human genes 0.000 claims description 8
- 230000002209 hydrophobic Effects 0.000 claims description 8
- 101700054655 CD8A Proteins 0.000 claims description 7
- 102100008191 CD8A Human genes 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000003612 virological Effects 0.000 claims description 7
- 102100009333 BTLA Human genes 0.000 claims description 6
- 101700047069 BTLA Proteins 0.000 claims description 6
- 101700056583 CD27 Proteins 0.000 claims description 6
- 102100019459 CD27 Human genes 0.000 claims description 6
- 101710040446 CD40 Proteins 0.000 claims description 6
- 102100013137 CD40 Human genes 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 102100019764 PDCD1 Human genes 0.000 claims description 6
- 108060007796 SPATA2 Proteins 0.000 claims description 6
- 101700080605 NUC1 Proteins 0.000 claims description 5
- 101700006494 nucA Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000008581 Brain Disease Diseases 0.000 claims description 4
- 102100019289 CD2 Human genes 0.000 claims description 4
- 101700024689 CD2 Proteins 0.000 claims description 4
- 102100019456 CD276 Human genes 0.000 claims description 4
- 101700015421 CD276 Proteins 0.000 claims description 4
- 102100019451 CD80 Human genes 0.000 claims description 4
- 101700080477 CD80 Proteins 0.000 claims description 4
- 101700013105 CD83 Proteins 0.000 claims description 4
- 102100008186 CD83 Human genes 0.000 claims description 4
- 206010052015 Cytokine release syndrome Diseases 0.000 claims description 4
- 206010014623 Encephalopathy Diseases 0.000 claims description 4
- 206010014625 Encephalopathy Diseases 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 4
- 101700079540 FAS Proteins 0.000 claims description 4
- 102100004898 HCST Human genes 0.000 claims description 4
- 101700079958 HCST Proteins 0.000 claims description 4
- 102100006815 IL2RA Human genes 0.000 claims description 4
- 101700082799 IL2RA Proteins 0.000 claims description 4
- 101700015336 ISG20 Proteins 0.000 claims description 4
- 210000000987 Immune System Anatomy 0.000 claims description 4
- 102000018358 Immunoglobulins Human genes 0.000 claims description 4
- 108060003951 Immunoglobulins Proteins 0.000 claims description 4
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 101710038601 TNFRSF14 Proteins 0.000 claims description 4
- 101710040533 TNFRSF8 Proteins 0.000 claims description 4
- 102100009538 TNFRSF8 Human genes 0.000 claims description 4
- 102100001100 TRAC Human genes 0.000 claims description 4
- 101700078141 TRAC Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000020411 cell activation Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims description 4
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims description 4
- 230000001506 immunosuppresive Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 230000002463 transducing Effects 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 102100001102 TRAT1 Human genes 0.000 claims description 3
- 101700050080 TRAT1 Proteins 0.000 claims description 3
- 101700083482 ZAP70 Proteins 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 230000001580 bacterial Effects 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 101710028178 ANPEP Proteins 0.000 claims description 2
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 102100003269 CD151 Human genes 0.000 claims description 2
- 101700010227 CD151 Proteins 0.000 claims description 2
- 101710039069 CD160 Proteins 0.000 claims description 2
- 102100014174 CD160 Human genes 0.000 claims description 2
- 102100005826 CD19 Human genes 0.000 claims description 2
- 101700087100 CD19 Proteins 0.000 claims description 2
- 101710031913 CD200R1 Proteins 0.000 claims description 2
- 102100017975 CD200R1 Human genes 0.000 claims description 2
- 102100000189 CD22 Human genes 0.000 claims description 2
- 101700020617 CD22 Proteins 0.000 claims description 2
- 102100016493 CD33 Human genes 0.000 claims description 2
- 101700017647 CD33 Proteins 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100003729 CD40LG Human genes 0.000 claims description 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 2
- 102100005828 CD5 Human genes 0.000 claims description 2
- 101700066525 CD5 Proteins 0.000 claims description 2
- 102100019283 CD52 Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100019453 CD7 Human genes 0.000 claims description 2
- 101700063101 CD7 Proteins 0.000 claims description 2
- 102100019443 CD79A Human genes 0.000 claims description 2
- 101700037975 CD79A Proteins 0.000 claims description 2
- 101700045471 CD79B Proteins 0.000 claims description 2
- 102100019449 CD79B Human genes 0.000 claims description 2
- 102100019450 CD81 Human genes 0.000 claims description 2
- 101700062651 CD81 Proteins 0.000 claims description 2
- 101710043956 CEACAM5 Proteins 0.000 claims description 2
- 102100011839 CEACAM6 Human genes 0.000 claims description 2
- 101710043949 CEACAM6 Proteins 0.000 claims description 2
- 101710043948 CEACAM7 Proteins 0.000 claims description 2
- 229920000033 CRISPR Polymers 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 102100001891 CTAG1A Human genes 0.000 claims description 2
- 101710004449 CTAG1A Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims description 2
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims description 2
- 102100016627 EPHA2 Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100016439 FAS Human genes 0.000 claims description 2
- 101700010580 FLO11 Proteins 0.000 claims description 2
- 101710030892 FLT1 Proteins 0.000 claims description 2
- 102100006565 FLT1 Human genes 0.000 claims description 2
- 102100008453 FOLH1 Human genes 0.000 claims description 2
- 101700036477 FOLH1 Proteins 0.000 claims description 2
- 101710042195 GAL9 Proteins 0.000 claims description 2
- 102100010042 GHR Human genes 0.000 claims description 2
- 101700076301 GHR Proteins 0.000 claims description 2
- 101700039255 GHRHR Proteins 0.000 claims description 2
- 102100003314 GHRHR Human genes 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 208000005017 Glioblastoma Diseases 0.000 claims description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 2
- 102100004115 ICAM1 Human genes 0.000 claims description 2
- 101700051176 ICAM1 Proteins 0.000 claims description 2
- 102100014263 IGF1R Human genes 0.000 claims description 2
- 101700025802 IGF1R Proteins 0.000 claims description 2
- 102100018760 IL3RA Human genes 0.000 claims description 2
- 101700029869 IL3RA Proteins 0.000 claims description 2
- 102100008185 IL6R Human genes 0.000 claims description 2
- 101710022769 IL6R Proteins 0.000 claims description 2
- 102100008192 IL6ST Human genes 0.000 claims description 2
- 101710022768 IL6ST Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100013180 KDR Human genes 0.000 claims description 2
- 101700033678 KDR Proteins 0.000 claims description 2
- 101710030888 KDR Proteins 0.000 claims description 2
- 101710036391 KLRC2 Proteins 0.000 claims description 2
- 102100012225 KLRC2 Human genes 0.000 claims description 2
- 102100019598 KLRF1 Human genes 0.000 claims description 2
- 101700086173 KLRF1 Proteins 0.000 claims description 2
- 102100004400 L1CAM Human genes 0.000 claims description 2
- 101700039980 L1CAM Proteins 0.000 claims description 2
- 102100016713 LCP2 Human genes 0.000 claims description 2
- 101700036603 LCP2 Proteins 0.000 claims description 2
- 102100004651 LGALS9 Human genes 0.000 claims description 2
- 102100009515 LRP5 Human genes 0.000 claims description 2
- 101700055993 LRP5 Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100000165 MS4A1 Human genes 0.000 claims description 2
- 101710010909 MS4A1 Proteins 0.000 claims description 2
- 102100006037 MUC1 Human genes 0.000 claims description 2
- 101700052761 MUC1 Proteins 0.000 claims description 2
- 102100006044 MUC16 Human genes 0.000 claims description 2
- 101700008449 MUC16 Proteins 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 101700001465 NBR1 Proteins 0.000 claims description 2
- 102100007544 NCAM1 Human genes 0.000 claims description 2
- 101700077124 NCAM1 Proteins 0.000 claims description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 102100019816 OSMR Human genes 0.000 claims description 2
- 101700032890 OSMR Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 102100006759 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102100002896 PSG2 Human genes 0.000 claims description 2
- 101700004495 PSG2 Proteins 0.000 claims description 2
- 101700008337 PSMA Proteins 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 2
- 101700025699 ROBO1 Proteins 0.000 claims description 2
- 102100017729 ROR1 Human genes 0.000 claims description 2
- 101710036428 ROR1 Proteins 0.000 claims description 2
- 101700058902 RORA Proteins 0.000 claims description 2
- 206010038038 Rectal cancer Diseases 0.000 claims description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 101710030435 SLAMF7 Proteins 0.000 claims description 2
- 102100017640 SLAMF7 Human genes 0.000 claims description 2
- 108091008153 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100006355 TLR7 Human genes 0.000 claims description 2
- 101700075266 TLR7 Proteins 0.000 claims description 2
- 102100016391 TLR9 Human genes 0.000 claims description 2
- 101710030862 TNFRSF13C Proteins 0.000 claims description 2
- 102100009743 TNFRSF13C Human genes 0.000 claims description 2
- 101710038526 TNFRSF1A Proteins 0.000 claims description 2
- 102100003095 TNFRSF1A Human genes 0.000 claims description 2
- 101710038524 TNFRSF1B Proteins 0.000 claims description 2
- 102100003105 TNFRSF1B Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims description 2
- 210000001635 Urinary Tract Anatomy 0.000 claims description 2
- 101700068327 VTCN1 Proteins 0.000 claims description 2
- 102100014952 VTCN1 Human genes 0.000 claims description 2
- 102100005283 ZAP70 Human genes 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 230000000735 allogeneic Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 2
- 201000005216 brain cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 108091006028 chimera Proteins 0.000 claims description 2
- 230000000139 costimulatory Effects 0.000 claims description 2
- 230000001461 cytolytic Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 230000005714 functional activity Effects 0.000 claims description 2
- 101710020181 fz Proteins 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 200000000018 inflammatory disease Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 claims description 2
- 201000009251 multiple myeloma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000001717 pathogenic Effects 0.000 claims description 2
- 244000052769 pathogens Species 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000000865 phosphorylative Effects 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002142 suicide Effects 0.000 claims description 2
- 230000004083 survival Effects 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 201000005161 thyroid carcinoma Diseases 0.000 claims description 2
- 230000002103 transcriptional Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102200023259 C6 Y19F Human genes 0.000 claims 1
- 102100013182 FLT4 Human genes 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 102000012850 Patched-1 Receptor Human genes 0.000 claims 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003394 haemopoietic Effects 0.000 claims 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 1
- 230000001177 retroviral Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000001131 transforming Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 description 2
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 102100016384 HAVCR2 Human genes 0.000 description 1
- 101710004393 HAVCR2 Proteins 0.000 description 1
- 101710036390 KLRK1 Proteins 0.000 description 1
- 102100012223 KLRK1 Human genes 0.000 description 1
- 102100011747 LPAR5 Human genes 0.000 description 1
- 101700059017 LPAR5 Proteins 0.000 description 1
- 108060009214 NRK Proteins 0.000 description 1
- 102100007268 PTCH1 Human genes 0.000 description 1
- 102100011501 PTCH2 Human genes 0.000 description 1
- 108010071083 Patched-2 Receptor Proteins 0.000 description 1
- 102100017732 ROR2 Human genes 0.000 description 1
- 102100003993 TGFBR1 Human genes 0.000 description 1
- 102100003994 TGFBR2 Human genes 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635450P | 2018-02-26 | 2018-02-26 | |
| US62/635,450 | 2018-02-26 | ||
| US201862676787P | 2018-05-25 | 2018-05-25 | |
| US62/676,787 | 2018-05-25 | ||
| US201862739792P | 2018-10-01 | 2018-10-01 | |
| US62/739,792 | 2018-10-01 | ||
| PCT/US2019/019014 WO2019165116A1 (en) | 2018-02-26 | 2019-02-21 | Compositions and methods for cellular immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514631A JP2021514631A (ja) | 2021-06-17 |
| JPWO2019165116A5 true JPWO2019165116A5 (ru) | 2022-03-01 |
Family
ID=65818064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544661A Pending JP2021514631A (ja) | 2018-02-26 | 2019-02-21 | 細胞免疫療法のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210079061A1 (ru) |
| EP (1) | EP3759130A1 (ru) |
| JP (1) | JP2021514631A (ru) |
| CN (1) | CN112041335A (ru) |
| AU (1) | AU2019224051A1 (ru) |
| CA (1) | CA3091138A1 (ru) |
| WO (1) | WO2019165116A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| US20210371540A1 (en) * | 2018-03-16 | 2021-12-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with mutated cd28 phosphorylation sites |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4104840A4 (en) * | 2020-02-13 | 2023-08-23 | Beijing Immunochina Pharmaceuticals Co., Ltd. | OPTIMIZATION OF A CHEMERA ANTIGEN RECEPTOR |
| AU2021312871A1 (en) * | 2020-07-21 | 2023-02-09 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| KR20230153482A (ko) * | 2021-04-08 | 2023-11-06 | 임비라 바이오파마수티컬스 컴퍼니 리미티드 | 케모카인 및 종양 관련성/특이성 항원을 전달하는 유전자 변형된 종양 용해성 단순 헤르페스 바이러스 |
| WO2023235819A1 (en) * | 2022-06-01 | 2023-12-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Recombinant receptors binding b cell activation factor receptor and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5525503A (en) * | 1993-09-28 | 1996-06-11 | Dana-Farber Cancer Institute, Inc. | Signal transduction via CD28 |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| DK1485475T3 (da) | 2002-03-15 | 2008-01-21 | Cellectis | Hybrid meganuklease og enkeltkædet maganuklease og brug deraf |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2007047859A2 (en) | 2005-10-18 | 2007-04-26 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2007051077A2 (en) | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US20110245167A1 (en) | 2008-12-12 | 2011-10-06 | The University Of Toledo | NaK-ATPase-Derived Peptide SRC Inhibitors and Ouabain Antagonists and Uses Thereof |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| DK2513146T3 (en) | 2009-12-18 | 2017-07-31 | Kancera Ab | Antibodies against ROR1 capable of inducing cell death by CLL |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| AU2011336650B2 (en) | 2010-12-01 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| PE20150336A1 (es) | 2012-05-25 | 2015-03-25 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn |
| WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
| CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| EP2848690B1 (en) | 2012-12-12 | 2020-08-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| SG10201804439PA (en) | 2013-12-20 | 2018-06-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
| JP6560235B2 (ja) * | 2014-01-13 | 2019-08-14 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ｆｃスペーサー領域に変異を有するキメラ抗原受容体（ＣＡＲ）及びそれらの使用方法 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| EP3201232A1 (en) | 2014-10-03 | 2017-08-09 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| US20180100026A1 (en) | 2015-04-15 | 2018-04-12 | California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| US11535662B2 (en) * | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| SG11201911838UA (en) * | 2017-07-07 | 2020-01-30 | H Lee Moffitt Cancer Center And Research Institute Inc | Chimeric antigen receptors with mutated cd28 costimulatory domains |
| CA3070861A1 (en) * | 2017-09-22 | 2019-03-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced nfkb signaling |
-
2019
- 2019-02-21 US US16/976,040 patent/US20210079061A1/en active Pending
- 2019-02-21 WO PCT/US2019/019014 patent/WO2019165116A1/en unknown
- 2019-02-21 CN CN201980028403.8A patent/CN112041335A/zh active Pending
- 2019-02-21 JP JP2020544661A patent/JP2021514631A/ja active Pending
- 2019-02-21 CA CA3091138A patent/CA3091138A1/en active Pending
- 2019-02-21 EP EP19712062.9A patent/EP3759130A1/en active Pending
- 2019-02-21 AU AU2019224051A patent/AU2019224051A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7490915B2 (ja) | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2020506700A5 (ru) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JP2020511136A5 (ru) | ||
| JP2022543702A (ja) | ヘテロ接合性の喪失に応答する細胞表面受容体 | |
| AU2018207300B2 (en) | T cells expressing a chimeric antigen receptor | |
| TW201904588A (zh) | 引導及導航控制蛋白質之製造及使用方法 | |
| JP2018521628A5 (ru) | ||
| WO2022012591A1 (zh) | 用于同种异体移植的工程化免疫细胞 | |
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ | |
| WO2021249462A1 (zh) | 表达nk抑制性分子的工程化免疫细胞及其用途 | |
| JP2023548844A (ja) | Ｃｄ７を標的にするキメラ抗原受容体及びその使用 | |
| JPWO2019191339A5 (ru) | ||
| JPWO2019191340A5 (ru) | ||
| Kim et al. | Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors | |
| JPWO2019165116A5 (ru) | ||
| EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| CN116249770A (zh) | 表达car的自然杀伤细胞与双特异性抗原结合分子作为癌症治疗剂的方法和组合物 | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| JPWO2021173985A5 (ru) | ||
| US11976297B2 (en) | Engineered immune cells with receptor cross-talk | |
| CN117247459A (zh) | 靶向cd69的工程化免疫细胞及其用途 | |
| RU2021108422A (ru) | Способы получения клеток, экспрессирующих химерный антигенный рецептор | |
| JPWO2021211948A5 (ru) |